China Pharma price to book ratio CPHI

Market value divided by the book value of the company's net assets, since 2011.

Today, Oct 23, 2026: 0.8×
9-year median: 0.7×
Against its 9-year history: 55th; percentile: 0 is its lowest day, 100 its highest
9-year range: 0.1× to 6.3×
Peer median: 1.5×

China Pharma's price to book ratio is 0.8× as of Oct 23, 2026.

That is above its 9-year median of 0.7×, close to the middle of its last 9 years.

Over that time it ranged from 0.1× in Oct 2017 to 6.3× in Feb 2021.

The median for 4 large drugmakers of a similar size is 1.5×.

Price to book ratio over time

median 0.7×

The dashed line is the 9-year median and the shaded band the middle half of its days.

Open the interactive chart, with overlays and comparisons

Year by year

Year	End of year	Low	High
2026 so far	0.8×	0.3×	1.9×
2025	0.8×	0.6×	1.0×
2024	0.6×	0.3×	0.7×
2023	0.7×	0.2×	2.1×
2022	1.7×	1.5×	3.4×
2021	3.3×	2.9×	6.3×
2020	2.5×	0.4×	3.4×
2019	0.4×	0.3×	0.6×
2018	0.2×	0.2×	0.5×
2017	0.1×	0.1×	0.2×
2016	0.1×	0.1×	0.1×
2015	0.1×	0.1×	0.2×
2014	0.1×	0.1×	0.2×
2013	0.1×	0.1×	0.1×
2012	0.1×	0.1×	0.3×
2011	0.2×	0.2×	0.3×

Against its peers

Companies in Drug Manufacturers - General nearest China Pharma's size, closest first, today.

Company	Price to book ratio
CPHIChina Pharma	0.8×
ATNMActinium Pharmaceuticals	1.6×
SPROSpero Therapeutics	1.5×
LFVNLifevantage	2.2×
NATRNatures Sunshine Products	1.3×
Peer median	1.5×

What the price to book ratio tells you

Market value divided by the accounting value of the company's net assets. Below 1 means the market values the business at less than what it owns on paper.

Book value misses brands, software and people, so asset-light companies always look expensive on it. Most useful for banks and industrials.

More on China Pharma

Valuation data, not investment advice. Prices as of Oct 23, 2026. Reported figures come from the company's filings with the SEC.